These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35195881)

  • 41. Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study.
    Wiebe S; Schnell D; Külzer R; Gansser D; Weber A; Wallenstein G; Halabi A; Conrad A; Wind S
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):461-469. PubMed ID: 27436099
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of dose modifications on the safety and efficacy of dacomitinib for
    Corral J; Mok TS; Nakagawa K; Rosell R; Lee KH; Migliorino MR; Pluzanski A; Linke R; Devgan G; Tan W; Quinn S; Wang T; Wu YL
    Future Oncol; 2019 Aug; 15(24):2795-2805. PubMed ID: 31313942
    [No Abstract]   [Full Text] [Related]  

  • 43. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
    Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
    Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.
    Tomkinson H; Kemp J; Oliver S; Swaisland H; Taboada M; Morris T
    BMC Clin Pharmacol; 2011 Mar; 11():3. PubMed ID: 21414193
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment.
    Shimasaki Y; Sakaki M; Itou M; Kobayashi T; Aso M; Kagawa T; Saiki T; Matsuno K; Sano Y; Shimizu K; Kuroda S; Koumura E
    Clin Drug Investig; 2018 Nov; 38(11):1041-1051. PubMed ID: 30194585
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
    Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
    Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
    Yin OQ; Gallagher N; Tanaka C; Fisher D; Sethuraman V; Zhou W; Lin TH; Heuman D; Schran H
    Clin Ther; 2009; 31 Pt 2():2459-69. PubMed ID: 20110053
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.
    Jänne PA; Ou SI; Kim DW; Oxnard GR; Martins R; Kris MG; Dunphy F; Nishio M; O'Connell J; Paweletz C; Taylor I; Zhang H; Goldberg Z; Mok T
    Lancet Oncol; 2014 Dec; 15(13):1433-1441. PubMed ID: 25456362
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials.
    Bentz Damholt B; Dombernowsky SL; Dahl Bendtsen M; Bisgaard C; Højby Rasmussen M
    Clin Pharmacokinet; 2021 Aug; 60(8):1015-1027. PubMed ID: 33754315
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A real-world study of dacomitinib in later-line settings for advanced non-small cell lung cancer patients harboring EGFR mutations.
    Li HS; Zhang JY; Yan X; Xu HY; Hao XZ; Xing PY; Wang Y
    Cancer Med; 2022 Feb; 11(4):1026-1036. PubMed ID: 35023313
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open-Label, Single-Dose, Parallel Group Study.
    Song I; Chen G; Wu J; Ilic K
    J Clin Pharmacol; 2023 Feb; 63(2):250-258. PubMed ID: 36089648
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment.
    Heinig R; Lambelet M; Nagelschmitz J; Alatrach A; Halabi A
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):619-628. PubMed ID: 30825073
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of Tropifexor, a Potent Farnesoid X Receptor Agonist, in Participants With Varying Degrees of Hepatic Impairment.
    Chen J; Gu J; Shah B; Stringer R; Reis da Silva Torrao L; Hackling M; Nidamarthy PK; Prince WT; Woessner R
    J Clin Pharmacol; 2022 Apr; 62(4):520-531. PubMed ID: 34738233
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment.
    van Herpen CM; Lassen U; Desar IM; Brown KH; Marotti M; de Jonge MJ
    Anticancer Drugs; 2013 Feb; 24(2):204-11. PubMed ID: 23197081
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
    Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Lee M; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Wu YL
    J Clin Oncol; 2018 Aug; 36(22):2244-2250. PubMed ID: 29864379
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
    Park K; Cho BC; Kim DW; Ahn MJ; Lee SY; Gernhardt D; Taylor I; Campbell AK; Zhang H; Giri N; Letrent SP; O'Connell J; Heo DS
    J Thorac Oncol; 2014 Oct; 9(10):1523-31. PubMed ID: 25521398
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).
    Cheng Y; Mok TS; Zhou X; Lu S; Zhou Q; Zhou J; Du Y; Yu P; Liu X; Hu C; Lu Y; Zhang Y; Lee KH; Nakagawa K; Linke R; Wong CH; Tang Y; Zhu F; Wilner KD; Wu YL
    Lung Cancer; 2021 Apr; 154():176-185. PubMed ID: 33721611
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.
    Ramalingam SS; Jänne PA; Mok T; O'Byrne K; Boyer MJ; Von Pawel J; Pluzanski A; Shtivelband M; Docampo LI; Bennouna J; Zhang H; Liang JQ; Doherty JP; Taylor I; Mather CB; Goldberg Z; O'Connell J; Paz-Ares L
    Lancet Oncol; 2014 Nov; 15(12):1369-78. PubMed ID: 25439691
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Effect of Hepatic Impairment on the Pharmacokinetics of Intravenously Administered Felcisetrag (TAK-954).
    Czerniak R; Cieslarová B; Kupčová V; Rosario M; Lock R; Dong C; Dukes G
    J Clin Pharmacol; 2022 Aug; 62(8):1006-1017. PubMed ID: 35253917
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
    Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
    Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.